Scientific Sessions
  • #AHA22
  • Virtual Experience Access
  • Sessions Posters
  • Late-Breaking Science
  • Daily Coverage
  • Industry Highlights
  • Featured Exhibitors
  • Program
  • Previews
Topics
  • Late-Breaking Science
  • Daily Coverage
  • Industry Highlights
  • Featured Exhibitors
  • Program
  • Previews
Resources
  • #AHA22
  • Virtual Experience Access
  • Sessions Posters
User Tools
  • Privacy Policy
  • Terms & Conditions
  • Accessibility Statement
Twitter iconFacebook iconInstagram iconYouTube iconPinterest iconLinkedIn icon
Nov 12th, 2020

National Heart Failure Initiative will improve outcomes and quality of life for patients with HF

Initiative supported by founding sponsor Novartis and national sponsor Boehringer Ingelheim Pharmaceuticals, Inc./Lilly USA, LLC.


2020 11 12 14 11 02

By 2030, more than 8 million people in the U.S. are projected to have heart failure, and deaths from HF are the primary cause of the plateau in age-adjusted death rate from CVD overall. In response,  AHA CEO Nancy Brown has announced the AHA’s National Heart Failure Initiative supported by founding sponsor Novartis and national sponsor Boehringer Ingelheim Pharmaceuticals, Inc./Lilly USA, LLC.

The initiative will enhance early identification and optimal treatment of HF, along with patient education, to increase healthy time at home and reduce all-cause mortality by 5%. The extensive expertise and infrastructure of the AHA, scientific partners and industry funders will be leveraged to develop concurrent interventions at several points along the patient care spectrum, including clinical and community touch points, specifically:

  • Establish and support learning health care system using quality improvement infrastructure with real-time feedback for identification of key areas for improvement and evaluation of evidence-based approaches.
  • Develop, implement and evaluate scalable patient empowerment and engagement tools that include personalized technology solutions and facilitate improved access to health care.

The initiative will use established AHA approaches of primary data collection, including the Get With The Guidelines® - HF program, to identify, implement and evaluate processes and develop new standards for HF patient management. Both health care and patient interventions will produce large-scale data collection from in-patient, out-patient and community settings resulting in generation of real-world evidence that will be used for characterization and dissemination of best practices.

Interesting Stories
MiCare Path joins the AHA CHTI and will integrate AHA science-based
Sponsored by MiCare Path
MiCare Path joins the AHA CHTI and will integrate AHA science-based
Data-driven precision medicine
Sponsored by Tempus
Data-driven precision medicine
Modern Wearable Defibrillation
Sponsored by Kestra Medical Technologies
Modern Wearable Defibrillation
New Double Take Videos from NEJM
Sponsored by NEJM Group
New Double Take Videos from NEJM
More Content
Manesh Patel
AHA22
#AHA 22 Closing Session: That’s a wrap
Nov 9th, 2022
Getty Images 1388100332
AHA22
Congratulations to the winners of the Wellness Challenge and Scavenger Hunt
Nov 8th, 2022
puppy snugglers
AHA22
Special Recognition to the Hinsdale Humane Society
Nov 8th, 2022
audience shot
AHA22
Trial results shed light on tool for assessing VTE risk, routine anticoagulation for non-hospitalized COVID patients, and clinical outcomes of open vs. endovascular surgery for advanced PAD
Nov 8th, 2022
audience shot
AHA22
Bivalirudin superior to unfractionated heparin in primary PCI following STEMI
Nov 8th, 2022
Panelists of the Mindful Disruption panel
Late-Breaking Science
Overcoming health disparities, health care advocates and mindfulness can better manage BP and CVD
Nov 7th, 2022
Medtech
AHA22
Medtech is getting smarter — and so is patient care
Nov 7th, 2022
med tech checking fluids in a hospital
AHA22
New digital hub offers professional education to complement lifelong learning
Nov 7th, 2022
Aha22 Sm 2334
AHA22
Trial results report on benefits of radial artery for CABG, use of prophylactic methylprednisolone and ECMO for patients in cardiogenic shock
Nov 7th, 2022
runner montage
AHA22
And the Health Tech Competition winner is…
Nov 7th, 2022
Aha Ss22 Days123 Pg1
AHA22
Read all about it
Nov 7th, 2022
Screen Shot 2022 11 06 At 10 45 03 Am
AHA22
Science, medicine must be a ‘relentless force’ in fighting misinformation
Nov 6th, 2022